Clinical Trials Logo

Clinical Trial Summary

This is a phase I study using the Erwinia form of asparaginase in place of the E. coli form using a standard re-induction regimen (Vincristine, Dexamethasone, Doxorubicin) for patients with relapsed ALL who have developed an allergy to the E. coli formulation. This study will administer the drug intravenously instead of the usual intramuscular route. The dose of Erwinia will be escalated in the absence of dose limiting toxicity. Patients must have first or second relapse ALL with a history of prior systemic reaction to E. coli asparaginase.


Clinical Trial Description

Significance

1. Substitution of Erwinase after E.coli asparaginase allergy has been standard practice despite the paucity of evidence regarding its efficacy and uncertainty about dose. Definition of an appropriate dose and schedule of Erwinase that provides reliable asparagine depletion may be useful for patients with clinical allergy to E. coli asparaginase, both in first remission or after relapse.

2. Patients in relapse may have a different level of asparagine synthesis than patients maintaining remission and require different asparaginase dosing.5

3. Intravenous administration provides more rapid and predictable asparagine depletion with less discomfort and danger of bleeding for often thrombocytopenic patients than intramuscular administration.

4. Vincristine, doxorubicin, asparaginase, and dexamethasone with dexrazoxane is clinically relevant for a population with first marrow relapse.

5. Vincristine, doxorubicin, asparaginase, and dexamethasone with dexrazoxane is clinically relevant for a population with second marrow relapse, if the duration of CR2 > 18 months year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00928200
Study type Interventional
Source Therapeutic Advances in Childhood Leukemia Consortium
Contact
Status Terminated
Phase Phase 1
Start date April 13, 2009
Completion date June 4, 2010

See also
  Status Clinical Trial Phase
Completed NCT03575325 - Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Phase 2
Terminated NCT01743807 - Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia Phase 1
Recruiting NCT04012879 - Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia Phase 1
Completed NCT03349281 - Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL Phase 1
Recruiting NCT04996160 - Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) Phase 1
Active, not recruiting NCT05192889 - Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Phase 1/Phase 2